Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology.

Amgen Inc. (NASDAQ:AMGN) was up $6.56 to $139.38 last week after a pair of regulatory announcements. FDA accepted and granted Priority Review to an NDA for ivabradine to treat chronic heart failure (CHF). The selective If channel inhibitor is already marketed as Procoralan in about 100 countries outside the U.S...